NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Zheng, Jin ^a,c   Li, Yan ^b   Yang, Jiandong ^a   Liu, Qiang ^c   Shi, Ming ^a   Zhang, Rui ^b   Shi, Hengjun ^c   Ren, Qinyou ^c   Ma, Ji ^a   Guo, Hang ^a   Tao, Yurong ^a   Xue, Yan ^a   Jiang, Ning ^a   Yao, Libo ^b   Liu, Wenchao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CD24 ANTIGEN; NDRG2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; N MYC DOWNSTREAM REGULATED GENE 2; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD24; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 79959239754     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-251     Document Type: Article

References (28)

1. Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S, Yang A, Han H, Zhang Y, Zhang J, Han W, Liu X. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem 2008, 21:239-250. 10.1159/000113765, 18209490.
2. Shen L, Zhao ZY, Wang YZ, Ji SP, Liu XP, Liu XW, Che HL, Lin W, Li X, Zhang J, Yao LB. Immunohistochemical detection of Ndrg2 in the mouse nervous system. Neuroreport 2008, 19:927-931. 10.1097/WNR.0b013e32830163d0, 18520995.
3. Boulkroun S, Fay M, Zennaro MC, Escoubet B, Jaisser F, Blot-Chabaud M, Farman N, Courtois-Coutry N. Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J Biol Chem 2002, 277:31506-31515. 10.1074/jbc.M200272200, 12072429.
4. Shon SK, Kim A, Kim JY, Kim KI, Yang Y, Lim JS. Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun 2009, 385:198-203. 10.1016/j.bbrc.2009.05.038, 19450561.
5. Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X, Yao LB. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol 2004, 10:3518-3521.
6. Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, Wu Y, Shen L, Zhang Y, Yang A, Han H, Zhang J, Yao L. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun 2007, 358:164-169. 10.1016/j.bbrc.2007.04.089, 17470364.
7. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, Kim JW, Song EY, Kim DM, Lee MN, Oh GT, Kim SJ, Park KC, Yoo HS, Choi JY, Yeom YI. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 2008, 68:4210-4220. 10.1158/0008-5472.CAN-07-5040, 18519680.
8. Wu GQ, Liu XP, Wang LF, Zhang WH, Zhang J, Li KZ, Dou KF, Zhang XF, Yao LB. Induction of apoptosis of HepG2 cells by NDRG2. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003, 19:357-360.
9. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998, 12:1241-1251.
10. Droz D, Zachar D, Charbit L, Gogusev J, Chrétein Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 1990, 137:895-905. 1877557, 1699423.
11. Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W. CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 1999, 58:795-802. 10.1097/00005072-199908000-00002, 10446804.
12. Kristiansen G, Schluns K, Yonwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br J Cancer 2003, 88:231-235. 10.1038/sj.bjc.6600702, 2377041, 12610508.
13. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003, 9:4906-4913.
14. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Leoning S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58:183-192. 10.1002/pros.10324, 14716744.
15. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002, 161:1215-1221. 10.1016/S0002-9440(10)64398-2, 1867310, 12368195.
16. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98:1176-1181. 10.1073/pnas.98.3.1176, 14728, 11158614.
17. Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 2005, 201:479-486. 10.1016/j.prp.2005.05.004, 16164042.
18. Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995, 55:4717-4721.
19. Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009, 15:5518-5527. 10.1158/1078-0432.CCR-09-0151, 19706825.
20. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008, 14:2056-2064. 10.1158/1078-0432.CCR-07-1473, 18381945.
21. Hsu HC, Su IJ, Lai MY, Chen DS, Chang MH, Chuang SM, Sung JL. Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol 1987, 50:45-50.
22. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 1993, 53:4691-4694.
23. Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol 2005, 17:49-54. 10.1097/01.cco.0000143682.45316.ae, 15608513.
24. Pirruccello SJ, LeBien TW. The human B-cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunolol 1986, 136:3779-3784.
25. Sagiv E, Arber N. The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepatol 2008, 2:125-133. 10.1586/17474124.2.1.125, 19072375.
26. Fidler IJ. Critical factors in the biology of human cancer metastasis: 28th G.H.A. Clowes memorial award lecture. Cancer Res 1990, 50:6130-6138.
27. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005, 65:10783-10793. 10.1158/0008-5472.CAN-05-0619, 16322224.
28. Lim SC. CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 2005, 59(Suppl 2):351-354.